Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet

Pereira, Liliane Desgualdo; Meng, Catarina; Amoedo, Manuel; Mendes, Maria Teresa de Sousa Costa Pinto Ferreira; Marques, Marco Alexandre Mateus Prazeres; Frazão, João; Weigert, André

doi:10.1016/j.nefro.2021.09.009

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In bone, PTH acts as a key modulator of this pathway: PTH inhibits sclerostin, thereby enhancing bone formation. Similarly, PTH inhibition leads to increased expression of sclerostin, underlining the close relationship between sclerostin and PTH [ 53 ]. However, there is a lack of consensus regarding the effects of PTH on Dkk1 [ 54 , 55 ].…”

Section: Novel Bone Markersmentioning

confidence: 99%

Novel Biomarkers of Bone Metabolism

Fernández-Villabrille,

Martín-Carro,

Martín-Vírgala

et al. 2024

Nutrients

View full text Add to dashboard Cite

Bone represents a metabolically active tissue subject to continuous remodeling orchestrated by the dynamic interplay between osteoblasts and osteoclasts. These cellular processes are modulated by a complex interplay of biochemical and mechanical factors, which are instrumental in assessing bone remodeling. This comprehensive evaluation aids in detecting disorders arising from imbalances between bone formation and reabsorption. Osteoporosis, characterized by a reduction in bone mass and strength leading to heightened bone fragility and susceptibility to fractures, is one of the more prevalent chronic diseases. Some epidemiological studies, especially in patients with chronic kidney disease (CKD), have identified an association between osteoporosis and vascular calcification. Notably, low bone mineral density has been linked to an increased incidence of aortic calcification, with shared molecules, mechanisms, and pathways between the two processes. Certain molecules emerging from these shared pathways can serve as biomarkers for bone and mineral metabolism. Detecting and evaluating these alterations early is crucial, requiring the identification of biomarkers that are reliable for early intervention. While traditional biomarkers for bone remodeling and vascular calcification exist, they suffer from limitations such as low specificity, low sensitivity, and conflicting results across studies. In response, efforts are underway to explore new, more specific biomarkers that can detect alterations at earlier stages. The aim of this review is to comprehensively examine some of the emerging biomarkers in mineral metabolism and their correlation with bone mineral density, fracture risk, and vascular calcification as well as their potential use in clinical practice.

show abstract

Section: Novel Bone Markersmentioning

confidence: 99%